Search

Displaying results 81 - 90 of 332 in total
  1. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for addition...

  2. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. … Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric

  3. Drug

    Cyclopentamine

    go.drugbank.com/drugs/DB08999
    ApprovedWithdrawn

    Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.

  4. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Active and viable hematopoietic progenitor cells, or hematopoietic stem cells (HSCs) express the cell surface marker CD34 which is critical for cell identification [A32216].

  5. Drug

    Sumatriptan

    go.drugbank.com/drugs/DB00669
    ApprovedInvestigational

    [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.

  6. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977.

  7. Drug

    Acamprosate

    go.drugbank.com/drugs/DB00659
    ApprovedInvestigational

    [L31758] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification[A997], unlike [naltrexone] and

  8. Drug

    Leflunomide

    go.drugbank.com/drugs/DB01097
    ApprovedInvestigational

    Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.

  9. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European

  10. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor. It was first approved in China - where it is indicated for a number of different ca...